PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Biomarkers Influence on Drug Discovery and Clinical Diagnostics Continues To Expand - New analysis from Frost & Sullivan, Advances in Biomarkers, finds that advances in techniques for identifying, developing, and validating biomarkers are continuously enhancing the efficiency and productivity of the drug development industry
Biomarkers Influence on Drug Discovery and Clinical Diagnostics Continues To Expand

 

NewswireToday - /newswire/ - Palo Alto, CA, United States, 2007/04/17 - New analysis from Frost & Sullivan, Advances in Biomarkers, finds that advances in techniques for identifying, developing, and validating biomarkers are continuously enhancing the efficiency and productivity of the drug development industry.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Biomarkers are being incorporated into several stages of drug discovery and development as they bear the potential to accelerate preclinical and clinical development. Furthermore, theranostic applications have penetrated the market, paving the way for the integration of biomarker applications in the diagnostics and pharmaceutical industry.

New analysis from Frost & Sullivan (technicalinsights.frost.com), Advances in Biomarkers, finds that advances in techniques for identifying, developing, and validating biomarkers are continuously enhancing the efficiency and productivity of the drug development industry. Biomarkers also enable elucidation of drug mechanisms, analysis of the drug efficacy and safety, and characterization of patient populations for clinical trials and clinical trial outcomes.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the Advances in Biomarkers, then send an email to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, email address, city, state, and country. We will send you the information via email upon receipt of the above information.

With increased diagnostic spending reducing the overall costs on therapy, enormous research is underway to bring to the market, biomarker-based screening tests that are simple, easy-to-use, and non-invasive. Prime areas of focus include the early diagnosis of cancer, cardiovascular disorders, and neurodegenerative disorders, such as, Alzheimer's disease and Parkinson's disease.

Although current technology platforms have discovered several biomarkers, the requirement of a validation method that possesses the ability to serve the purpose and regulatory conditions hinder further development. Therefore, due to the major bottleneck at biomarker validation, the rate of biomarker discovery exceeds that of preliminary support by many folds.

Discovery of novel markers, based on global genomic or proteomic analysis, is still very new. However, thousands of acknowledged biomarkers have been identified. Yet, relatively fewer have crossed over to be integrated in drug discovery programs or clinical application stages due to the lack of validated biomarkers.

“The ‘-omics’ technology platforms integrated with systems biology approach hold the key to biomarker identification and are poised to take the industry by storm,” cites Frost & Sullivan Research Analyst Sandhya Kamath. “A third generation of ‘omics’ or the metabolomics is underway, which takes advantage of biochemical pathway information and holds potential to deliver cost-effective technologies to the market.”

However, with the clinical market questioning the specificity and sensitivity of new biomakers, the degree of acceptance is fairly low with new technologies such as microfluidics-based separation. Furthermore, on the application front, pharmaceutical companies are waiting to see if other companies are able to reap benefits from biomarker studies. This presents a major setback to the biomarker advancement as it can take years to demonstrate the significant financial impact on drug discovery efforts.

There is also a growing concern in the field of drug discovery regarding cost and duration of clinical trials that are reaching enormous proportions. Although biomarkers initially increase the cost of clinical development, as larger biomarker portfolios are developed and other drug discovery technologies are integrated, the cost and duration of clinical development are likely to drop.

“It is essential for companies to invest more in the validation phase of biomarker research to successfully bring to the market reliable, specific and sensitive biomarkers,” says Kamath. “Biomarkers have huge potential for diagnostic markets, provided routine clinical diagnostics, shed all skepticism and adopt the biomarker approach.”

Advances in Biomarkers is part of the Technical Insights - Healthcare Subscription, which also includes the following research services: technology developments in functional proteomics, personalized medication – technology trend analysis, and advances in drug discovery technology. All research services included in subscriptions provide detailed market opportunities and industry trends, evaluated following extensive interviews with market participants. Interviews with the press are available.

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective, and combines ongoing analysis of markets, technologies, econometrics, and demographics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Metropolitan Area

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Biomarkers Influence on Drug Discovery and Clinical Diagnostics Continues To Expand

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Melina Trevino 
210.247.2440 melina.trevino[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  MagLar, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)